ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

The information in this Item 2.02, including Exhibit 99.1 attached, is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Attached as Exhibit99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated January 31, 2018, announcing our results of operations for the fourth quarter and fiscal year period ended December 31, 2017, including, among other things, unaudited operating results for those periods.

Item 2.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced, on June 1, 2017, Derica Rice, executive vice president global services and chief financial officer of the company, announced his retirement, effective December 31, 2017.

On September 29, 2017, the company announced that the board of directors elected Joshua Smiley as senior vice president and chief financial officer of the company, effective January 1, 2018. All company officers are elected to one-year terms expiring at the company’s annual meeting of the board of directors in May. Accordingly, Mr. Smiley’s initial term of office as senior vice president and chief financial officer will expire on the date of the next annual meeting of the board, to be held on May 7, 2018.

There was not and is not any arrangement or understanding between Mr. Smiley and any other person to which Mr. Smiley was selected as an officer.

Mr. Smiley, age 48, has served as senior vice president and treasurer of the company since October 2016. Mr. Smiley joined Lilly in 1995 as a financial analyst and has held a broad range of corporate strategy and financial management positions at the company. Before assuming his current position, he served as senior vice president and controller and chief financial officer of Lilly Research Laboratories from 2011 to 2016.

In connection with Mr. Smiley’s appointment as senior vice president and chief financial officer, effective January 1, 2018, Mr. Smiley will receive an annualized base salary of $875,000 and will be eligible for annualized non-equity incentive plan compensation of $831,250, based on his target bonus under the company’s bonus plan.

Item 2.02. Financial Statements and Exhibits

Exhibit NumberDescription

99.1Press release dated January 31, 2018

LILLY ELI & CO Exhibit
EX-99.1 2 q417lillysalesandearningsp.htm EXHIBIT 99.1 Exhibit January 31,…
To view the full exhibit click here

About ELI LILLY AND COMPANY (NYSE:LLY)

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.